Login to Your Account

Zai nabs China rights to T790-mutation NSCLC drug in Hanmi agreement

By Shannon Ellis
Staff Writer

Tuesday, November 24, 2015

SHANGHAI – Zai Labs Ltd., of Shanghai, signed a China rights deal, including Hong Kong and Macau, for a coveted late-stage targeted non-small-cell lung cancer (NSCLC) therapy, HM61713, from Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription